You are viewing the site in preview mode

Skip to main content

Table 4 The variables used in the probabilistic sensitivity analysis, with their associated uncertainty and distributions

From: Cost-effectiveness of palivizumab in infants with congenital heart disease: a Swedish perspective

Variable Mean value Standard error (SE) Distribution
Risk of RSV-hospitalization 9.7% 0.010 beta
HR RSV hospitalization (proph) 0.55 0.055 lognormal
Death from RSV hospitalization 3.7% 0.004 beta
Proportion delayed surgeries due to RSV-hosp 30.0% 0.030 beta
Proportion general complication from delayed surgery 40.0% 0.040 beta
Death (compl., delayed surgery) 1.0% 0.001 beta
LOS, RSV hospitalization 13.27 1.33 gamma
LOS, RSV hospitalization (proph) 10.79 1.08 gamma
LOS, ICU 7.32 0.73 gamma
LOS, ICU (proph) 2.97 0.30 gamma
Days with suppl. Oxygen 10.44 1.04 gamma
Days with suppl. Oxygen (proph) 5.24 0.52 gamma
Days with mechanical ventilation 5.62 0.56 gamma
Days with mechanical ventilation (proph) 1.24 0.12 gamma
Days with ECMO 8.17 0.82 gamma
Days with ECMO (proph) 8.17 0.82 gamma
Days with CPAP 3.50 0.35 gamma
Days with CPAP (proph) 3.50 0.35 gamma
RSV hosp (cost per day) 1197 EUR 120 gamma
ICU (cost per day) 605 EUR1 60 gamma
Suppl. oxygen (cost per day) 344 EUR 34 gamma
Mechanical ventilation (cost per day) 344 EUR 34 gamma
ECMO (cost per day) 8592 EUR 859 gamma
CPAP (cost per day) 2141 EUR 214 gamma
first injection (kg) 5.00 0.50 normal
second injection (kg) 5.40 0.54 normal
third injection (kg) 5.80 0.58 normal
fourth injection (kg) 6.40 0.64 normal
fifth injection (kg) 7.00 0.70 normal
Annual cost asthma 1440 EUR 144 gamma
Cost of general CHD-complication (annual) 21,506 EUR 2151 gamma
Base utility 0.89 0.089 beta
Utility decrement of RSV hosp 0.10 0.010 beta
Asthma utility 0,79 0,079 beta
Utility decrement of heart complication 0,10 0,010 beta
\